“[PCSK9 inhibitors] represent a new era of hope for us,” said Katherine Wilemon, founder and president of the FH Foundation, an advocacy group. “We tend to take everything out there that is available, and even with that we can’t get our LDL levels down to a ‘safe’ level.”Ms. Wilemon, whose organization gets contributions from drug companies, suffered a heart attack in 2006, at age 39. About nine months ago, even though she was taking a statin and other drugs, her LDL level was about 167, much higher than the 70 or 100 that would be recommended for her. But when she began taking one of the new drugs in a study, her LDL levels dropped below 50.
To read the full article, CLICK HERE
More articles about the new PCSK9 therapy:
Kexin checks in: Praluent lodges key first approval stateside for Regeneron/Sanofi, label not left to ‘Amgen-ation’ – BioWorld